chitosan-cyclodextrin-curcumin-genistein nanocomplexs (Transgenex Nanobiotech)

N/A

Report date: 2025/03/14 20:00:48
NME

Base Information

Drug Namechitosan-cyclodextrin-curcumin-genistein nanocomplexs (Transgenex Nanobiotech)
Drug Alias Name3CG-nanocomplexes (TGN)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtein-tyrosine kinases inhibitorsEstrogen receptors modulatorsAndrogen Receptor degraders
TargetsEstrogen receptorsProtein-tyrosine kinasesAndrogen Receptor
Therapy Area/IndicationsHormone-Resistant Prostate Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesTransGenex Nanobiotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTransGenex Nanobiotech Inc
Active IndicationsN/A
Inactive IndicationsHormone-Resistant Prostate Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A